Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04690699 · ClinicalTrials.gov registry record · Phase 1
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
A Phase 1 study, sponsored by Istari Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04690699 is a Phase 1 study that was terminated before completion, run by Istari Oncology. The registered enrollment target is 4 participants.
The verdict
NCT04690699, a Phase 1 study, was terminated before completion, sponsored by Istari Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a Phase 1/2, open-label, multi-center, single arm basket study evaluating the administration of lerapolturev ± anti programmed cell death protein 1 (PD 1)/programmed death-ligand 1 (PD L1) monoclonal antibody (mAb) (which will be referred to throughout this protocol as "anti-PD-1/L1 therapy") therapy in adult patients with solid tumor cancers. Non-muscle invasive Bladder Cancer has been selected as the tumor specific cancer of interest for enrollment.
Interventions
- BIOLOGICAL Lerapolturev
- OTHER 5% DDM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2024-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04690699
The ClinicalTrials.gov registry entry for NCT04690699 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Istari Oncology, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lerapolturev is the first listed.
NCT04690699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04690699 about?
NCT04690699 is a clinical study titled "LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors". This is a Phase 1/2, open-label, multi-center, single arm basket study evaluating the administration of lerapolturev ± anti programmed cell death protein 1 (PD 1)/programmed death-ligand 1 (PD L1) monoclonal antibody (mAb) (which will be referred to throughout this protocol as "anti-PD-1/L1 therapy"...
What is the current status of trial NCT04690699?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-08-01. Estimated completion is 2024-06-12.
What interventions are being tested in trial NCT04690699?
The interventions under investigation include: Lerapolturev (BIOLOGICAL), 5% DDM (OTHER).
Who is sponsoring clinical trial NCT04690699?
This trial is sponsored by Istari Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.